Connect with us

Headlines

Outdoor Eyewear Company Names US CEO

The firm is based in France.

mm

Published

on

WILLISTON, VT — Julbo Eyewear, a French eyewear brand based in the Jura Mountains, has named David Crothers as CEO of its U.S. operations.

Crothers has been marketing manager at Julbo, which focuses on outdoor eyewear, since 2015, growing the brand’s visibility within the ski and bike categories.

In 2008, Crothers started the climbing website Climberism, which was eventually absorbed by Height of Land Publications. Crothers managed Height of Land’s digital assets and eventually was promoted to photo editor for all Height of Land publications, before moving into the marketing role at Julbo.

“I’ve got some big shoes to fill. Nick has been the face of the brand for a long time,” Crothers says. “I’m extremely excited for the opportunity. Julbo is a terrific brand and we have a great team.”

Julbo will continue building on its core mountain and outdoor heritage while focusing on growing its ski, bike and lifestyle categories, according to a press release.

“We strongly believe that with Dave’s experience, combined with the full support of France, we will continue to build our presence in the U.S. market,” said Pierre Burgelin, international sales director for the company.

Advertisement

Advertisement

SPONSORED VIDEO

SPONSORED BY REICHERT

When You’re Passionate About Eye Care, the Right Technology Matters

Lisa Genovese, O.D., strives to give her patients the very best. At Insight Eye Care’s multiple locations, Dr. Genovese provides optimal care for her patients using the Reichert® Phoroptor® VRx Digital Refraction System. In this second Practice Profile Video from Reichert’s “Passionate About Eye Care” series, take a closer look and see how this eye care professional achieved a better work-life balance with equipment that’s designed and engineered in the U.S.A.

Promoted Headlines

Headlines

Several Eyecare Drugs in Short Supply, FDA Says

They include staple items.

mm

Published

on

Thirteen ophthalmic drugs or products are currently in a state of shortage, according to the U.S. Food and Drug Administration.

They include solutions, ointments, emulsions, suspensions and injections, the American Optometric Association reports. Another four ophthalmic products were recently discontinued altogether.

The FDA claims in a new report that older, lower-cost drugs face supply troubles far more often than brand-name options, AOA reports. Among the ophthalmic drugs or products in shortage are staple items such as fluorescein strips and solutionsdilation dropsglaucoma medicationsantibiotics and antivirals.

According to AOA:

Published Oct. 29 by an FDA-convened inter-agency Drug Shortages Task Force, the report, “Drug Shortages: Root Causes and Potential Solutions,” analyzed 163 drugs that went into shortage from 2013 to 2017 and found the majority were “financially unattractive drugs” for manufacturers. Of the 163 drugs, 109 (67%) had generic versions on the market and had a median time since first approval of nearly 35 years. So many years off patent, these drugs sold for a median per unit price of only $8.73, the FDA notes.

AOA Chief Public Health Officer Michael Duenas, OD, said, “A doctor of optometry, in their public health role, should monitor services and needed supplies to determine that they are useful and accessible to all individuals within their community who may need that particular service or supply. Doctors of optometry are encouraged to report deficiencies to the AOA and agencies overseeing shortages, such as FDA’s Center for Drug Evaluation and Research (CDER) Drug Shortage Program at drugshortages@fda.hhs.gov.”

Continue Reading

Headlines

Japanese Women Seek Right to Wear Eyeglasses at Work

Some companies require female workers to wear contacts instead.

mm

Published

on

Women in Japan are calling for an end to company policies that forbid them from wearing eyeglasses, Fortune reports.

The issue appeared in the news recently, with Nippon TV reporting on companies that have such a ban in place, requiring female employees who need vision correction to wear contact lenses instead. That report sparked the hashtag “glasses ban” on Twitter.

Fortune quoted Banri Yanagi, a 40-year-old sales associate in Tokyo, saying, “The emphasis on appearance is often on young women and wanting them to look feminine.”

Yanagi added that it’s “strange” to prohibit eyeglasses for women but allow them for men.

Employees have also rallied against requirements at some companies for women to wear makeup and/or high heels.

Read more at the Fortune

Continue Reading

Headlines

Eye Health Firm Plans Job Cuts

It will focus resources on Dextenza.

mm

Published

on

BEDFORD, MA — Ocular Therapeutix Inc., a biopharmaceutical company focused on therapies for eye conditions and diseases, announced an operational restructuring plan.

The plan is expected to result in about $11 million in annualized savings through personnel reductions and $14 million in “one-time program deferrals,” according to a press release. The company did not say how many jobs would be cut.

With the restructuring, the company is looking to focus resources on Dextenza, an FDA-approved corticosteroid indicated for the treatment of ocular inflammation and pain following ophthalmic surgery.

“We have elected to restructure Ocular in order to maximize the opportunity we have with DEXTENZA and our pipeline,” said Antony Mattessich, president and CEO. “We will use a portion of the savings generated to increase the size of our commercial field force to broaden our national reach and increase DEXTENZA promotional capabilities. Additionally, the savings are anticipated to extend our cash runway through the end of 2020 and provide an improved financial position as we build the Company for the long term.”

According to the press release:

The restructuring represents a strategic realignment and commitment by the Company to allocate capital and resources to maximize the commercial opportunity of DEXTENZA® and focus resources on progressing key pipeline assets, including completion of its DEXTENZA Phase 3 trial in allergic conjunctivitis and completion of Phase 1 trials of OTX-TIC for the treatment of glaucoma and ocular hypertension and OTX-TKI for the treatment of wet age-related macular degeneration. The Company believes the savings, combined with projected sales of DEXTENZA and cash and cash equivalents, will result in an extension of the Company’s current cash runway through the fourth quarter of 2020.

Continue Reading

Advertisement

Advertisement

Subscribe


BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Most Popular